Is Shield Therapeutics plc a better bet than AstraZeneca plc?

Does the small-cap potential of Shield Therapeutics plc (LON: STX) beat the blue chip reliability of AstraZeneca plc (LON: AZN) in the pharma stakes?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Do hares always beat tortoises? Are speedboats better than ocean liners? Are small-cap startup companies better than the established giants for growing your investment cash?

A lucrative startup?

The question must have crossed a few minds when reading today’s first-half results from Shield Therapeutics (LSE: STX), which floated on AIM as recently as February 2016.

Shield describes itself as a “specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals.” It reported its first revenues, of £240,000, from sales of its iron deficiency anaemia treatment Feraccru after it was approved in February. It’s a modestly-priced medication, but chief executive Carl Sterritt described its pricing agreements as attractive, and sales should also commence in Germany in October.

It’s hard to put any kind of valuation on Shield’s 159p shares at the moment, as there are no profits forecast yet, and consistent losses pencilled-in for this year and next. The firm did have £28.4m in cash on the books at 30 June but with pre-tax losses of £18m-£19m per year forecast for this year and next, there’s going to be some more fundraising needed before any profits start rolling in.

Where does this leave Shield Therapeutics as an investment possibility? It’s not a total blue-sky punt as it does have a marketable product and does actually have sales cash coming in, but other than that I see it as pretty much straight gambling if you invest right now — it looks like one of those companies that could make you a very big profit it it comes good, but could lose you your stake if it doesn’t.

Tried and trusted?

Are you better, then, to stick with an established blue chip pharmaceuticals company like AstraZeneca (LSE: AZN)? AstraZeneca was struggling against the expiry of patents and increased competition from generic drugs when Pascal Soriot took over as chief executive in October 2012.

Mr Soriot’s shake-up was severe, and it was always going to take a few years to rein in the firm’s falling earnings and return them to growth. I’d optimistically hoped for EPS growth by 2017, but that seems unlikely now, with falls of 2%-3% forecast for this year and next. Still, if we see EPS growth in 2018, that really won’t be a bad turnaround result at all.

I’m a little surprised that the price has spiked by a third since the middle of June to 5,164p. That’s taken the shares to a forward P/E multiple of 16.4 for 2017, though interim results on 28 July saw second-quarter falls across the board. It was all in line with expectations, mind, and there’s really nothing new that wasn’t known six months ago.

I suspect the price recovery is simply down to investors re-appraising the value of good old safe and solid shares like our big pharmaceuticals players, partly in the sobering light of the EU referendum result. And they’re realising that P/E ratings of around 16 or so aren’t at all stretching for dependable investments providing dividend yields in excess of 4% and which should be generating profits for decades to come.

At least, that’s the way I see AstraZeneca, and it would nice to think the market does too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »